Home › Compare › BTAX vs NOBL

BTAX vs NOBL: Dividend Comparison 2026

BTAX yields 2000000.00% · NOBL yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTAX wins by $4.879226400974806e+39M in total portfolio value
10 years
BTAX
BTAX
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full BTAX calculator →
NOBL
NOBL
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full NOBL calculator →

Portfolio growth — BTAX vs NOBL

📍 BTAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTAXNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTAX + NOBL cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BTAX pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTAX
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, BTAX beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTAX + NOBL for your $10,000?

BTAX: 50%NOBL: 50%
100% NOBL50/50100% BTAX
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTAX buys
0
NOBL buys
0
No recent congressional trades found for BTAX or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTAXNOBL
Forward yield2000000.00% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$4.879226400974806e+39M$28.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$899.19
Total dividends collected$4.879195005460081e+39M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BTAX vs NOBL ($10,000, DRIP)

YearBTAX PortfolioBTAX Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,120$420.00+$200.00M → BTAX
2$3,738,731,768,458$3,738,517,757,009.35$12,357$458.31+$3738731.76M → BTAX
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,721$499.76+$65315062866.92M → BTAX
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,227$544.58+$1066400830062625.00M → BTAX
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$16,885$593.02+$16272182796453826560.00M → BTAX
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$18,713$645.34+$2.3205424011366188e+23M → BTAX
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$20,724$701.81+$3.0927990661046884e+27M → BTAX
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$22,938$762.73+$3.8524105697352695e+31M → BTAX
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$25,372$828.41+$4.484688260147987e+35M → BTAX
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$28,047$899.19+$4.879226400974806e+39M → BTAX

BTAX vs NOBL: Complete Analysis 2026

BTAX — Stock

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.

Full BTAX Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →
📬

Get this BTAX vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTAX vs SCHDBTAX vs JEPIBTAX vs OBTAX vs KOBTAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.